Revvity(RVTY) ZACKS·2025-01-31 19:15Core Viewpoint - Revvity, Inc. reported strong fourth-quarter 2024 results with adjusted EPS of $1.42, exceeding estimates and showing a year-over-year improvement of 13.6% [1][2] Financial Performance - GAAP EPS from continuing operations was 78 cents, up from 64 cents in the prior year, including 5 cents from discontinued operations [2] - Total revenues reached $729.3 million, reflecting a 4.8% year-over-year increase, but slightly missing the Zacks Consensus Estimate by 0.1% [3] Segment Analysis - Life Sciences segment revenues were $336 million, up 5% year-over-year, with adjusted operating income of $131 million, an 11% increase [4] - Diagnostics segment revenues totaled $393 million, a 4.5% year-over-year increase, with organic growth of 6% [4] Margin and Expense Analysis - Selling, general and administrative expenses decreased by 4.8% to $244.3 million, while research and development expenses were $49.2 million, down 0.8% [6] - Adjusted operating income improved by 15.4% to $221.3 million, with an adjusted operating margin of 28.3%, expanding by 280 basis points [6] Cash Flow and Financial Position - The company ended Q4 2024 with cash and cash equivalents of $1.16 billion, down from $1.23 billion in the previous quarter [7] - Net cash provided by operating activities was $174.2 million, compared to a net cash used of $196.6 million in the year-ago quarter [7] 2025 Guidance - For 2025, Revvity expects adjusted EPS in the range of $4.90-$5.00 and revenues between $2.80-$2.85 billion, with Zacks Consensus Estimates at $4.97 and $2.87 billion respectively [8]